{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:42Z","timestamp":1790167182379,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T00:00:00Z","timestamp":1385078400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10549-013-2777-6","type":"journal-article","created":{"date-parts":[[2013,11,21]],"date-time":"2013-11-21T01:49:37Z","timestamp":1384998577000},"page":"171-179","source":"Crossref","is-referenced-by-count":14,"title":["CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial"],"prefix":"10.1007","volume":"143","author":[{"given":"Vincent O.","family":"Dezentj\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. N.","family":"Van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith M.","family":"Vletter-Bogaartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahar","family":"Van der Straaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A. M.","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elma Meershoek-Klein","family":"Kranenbarg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els M.","family":"Berns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Seynaeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"Putter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J. H.","family":"Van de Velde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W. R.","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,22]]},"reference":[{"key":"2777_CR1","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(02)11774-0","volume":"360","author":"V Stearns","year":"2002","unstructured":"Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D (2002) Hot flushes. Lancet 360:1851\u20131861","journal-title":"Lancet"},{"key":"2777_CR2","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312\u20139318","journal-title":"J Clin Oncol"},{"key":"2777_CR3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/tpj.2009.14","volume":"9","author":"JM Rae","year":"2009","unstructured":"Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258\u2013264","journal-title":"Pharmacogenomics J"},{"key":"2777_CR4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(08)70259-6","volume":"9","author":"J Cuzick","year":"2008","unstructured":"Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143\u20131148. doi: 10.1016\/S1470-2045(08)70259-6","journal-title":"Lancet Oncol"},{"key":"2777_CR5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L et al (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421\u2013426. doi: 10.1007\/s10549-007-9612-x","journal-title":"Breast Cancer Res Treat"},{"key":"2777_CR6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2009.25.0894","volume":"28","author":"VO Dezentje","year":"2010","unstructured":"Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423\u20132429","journal-title":"J Clin Oncol"},{"key":"2777_CR7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441\u2013451. doi: 10.1093\/jnci\/djs125","journal-title":"J Natl Cancer Inst"},{"key":"2777_CR8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jnci\/djs304","volume":"104","author":"Y Nakamura","year":"2012","unstructured":"Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: cYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1264\u20131268. doi: 10.1093\/jnci\/djs304","journal-title":"J Natl Cancer Inst"},{"key":"2777_CR9","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/jnci\/djs312","volume":"104","author":"PD Pharoah","year":"2012","unstructured":"Pharoah PD, Abraham J, Caldas C (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:1263\u20131264. doi: 10.1093\/jnci\/djs312","journal-title":"J Natl Cancer Inst"},{"key":"2777_CR10","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jnci\/djs305","volume":"104","author":"V Stanton Jr","year":"2012","unstructured":"Stanton V Jr (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1265\u20131266. doi: 10.1093\/jnci\/djs305","journal-title":"J Natl Cancer Inst"},{"key":"2777_CR11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.2012.44.6625","volume":"31","author":"H Brauch","year":"2013","unstructured":"Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN et al (2013) Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 31:176\u2013180. doi: 10.1200\/JCO.2012.44.6625","journal-title":"J Clin Oncol"},{"key":"2777_CR12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(10)62312-4","volume":"377","author":"CJ Velde van de","year":"2011","unstructured":"van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321\u2013331","journal-title":"Lancet"},{"key":"2777_CR13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2353\/jmoldx.2010.100047","volume":"12","author":"R Baak-Pablo","year":"2010","unstructured":"Baak-Pablo R, Dezentje V, Guchelaar HJ, van der Straaten T (2010) Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn 12:6\u2013749","journal-title":"J Mol Diagn"},{"key":"2777_CR14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-009-0309-1","volume":"117","author":"NL Henry","year":"2009","unstructured":"Henry NL, Rae JM, Li L, Azzouz F, Skaar TC, Desta Z et al (2009) Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 117:571\u2013575","journal-title":"Breast Cancer Res Treat"},{"key":"2777_CR15","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429\u20131436","journal-title":"JAMA"},{"key":"2777_CR16","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2009.25.7246","volume":"28","author":"K Kiyotani","year":"2010","unstructured":"Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28:1287\u20131293","journal-title":"J Clin Oncol"},{"key":"2777_CR17","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW et al (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89:718\u2013725. doi: 10.1038\/clpt.2011.32","journal-title":"Clin Pharmacol Ther"},{"key":"2777_CR18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(09)70030-0","volume":"10","author":"TL Lash","year":"2009","unstructured":"Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825\u2013833","journal-title":"Lancet Oncol"},{"key":"2777_CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-08-2006","volume":"15","author":"VO Dezentje","year":"2009","unstructured":"Dezentje VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H (2009) Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15\u201321","journal-title":"Clin Cancer Res"},{"key":"2777_CR20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-009-0463-5","volume":"118","author":"AS Dieudonne","year":"2009","unstructured":"Dieudonne AS, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D et al (2009) Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users. Breast Cancer Res Treat 118:531\u2013538","journal-title":"Breast Cancer Res Treat"},{"key":"2777_CR21","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/bcr2629","volume":"12","author":"JE Abraham","year":"2010","unstructured":"Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C et al (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12:R64","journal-title":"Breast Cancer Res"},{"key":"2777_CR22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1158\/0008-5472.SABCS-09-33","volume":"69","author":"M Goetz","year":"2009","unstructured":"Goetz M, Berry D, Klein T, International Tamoxifen Pharmacogenomics Consortium (2009) Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the international tamoxifen pharmacogenomics consortium. Cancer Res 69:33","journal-title":"Cancer Res"},{"key":"2777_CR23","first-page":"363","volume":"140","author":"VO Dezentje","year":"2010","unstructured":"Dezentje VO, Van Schaik RH, Vletter-Bogaartz JM, Wessels JA, Hille ET, Seynaeve C et al (2010) Pharmacogenetics of tamoxifen in relation to disease-free survival in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. J Clin Oncol 140:363\u2013373","journal-title":"J Clin Oncol"},{"key":"2777_CR24","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.1158\/1078-0432.CCR-11-0860","volume":"17","author":"MP Goetz","year":"2011","unstructured":"Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M et al (2011) Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res 17:6944\u20136951","journal-title":"Clin Cancer Res"},{"key":"2777_CR25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452\u2013460. doi: 10.1093\/jnci\/djs126","journal-title":"J Natl Cancer Inst"},{"key":"2777_CR26","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.1200\/JCO.2008.16.8377","volume":"26","author":"Y Jin","year":"2008","unstructured":"Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S et al (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849\u20135854","journal-title":"J Clin Oncol"},{"key":"2777_CR27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-008-0264-2","volume":"115","author":"AA Onitilo","year":"2009","unstructured":"Onitilo AA, McCarty CA, Wilke RA, Glurich I, Engel JM, Flockhart DA et al (2009) Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat 115:643\u2013650","journal-title":"Breast Cancer Res Treat"},{"key":"2777_CR28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/clpt.2010.143","volume":"88","author":"DF Hayes","year":"2010","unstructured":"Hayes DF, Skaar TC, Rae JM, Henry NL, Nguyen AT, Stearns V et al (2010) Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther 88:626\u2013629","journal-title":"Clin Pharmacol Ther"},{"key":"2777_CR29","doi-asserted-by":"crossref","unstructured":"Grabinski JL, Chisholm G, Smith LS, Drengler RL, Kalter S, Rodriguez G et al (2008). ER alpha genotypes and breast cancer recurrence. J Clin Oncol 26(15S):501","DOI":"10.1200\/jco.2008.26.15_suppl.501"},{"key":"2777_CR30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/0091270009359182","volume":"50","author":"S Borges","year":"2010","unstructured":"Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S et al (2010) Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 50:450\u2013458","journal-title":"J Clin Pharmacol"},{"key":"2777_CR31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0888-7543(02)00031-9","volume":"81","author":"B Fletcher","year":"2003","unstructured":"Fletcher B, Goldstein DB, Bradman AL, Weale ME, Bradman N, Thomas MG (2003) High-throughput analysis of informative CYP2D6 compound haplotypes. Genomics 81:166\u2013174","journal-title":"Genomics"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2777-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-013-2777-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-013-2777-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,3]],"date-time":"2019-08-03T17:47:13Z","timestamp":1564854433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-013-2777-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["2777"],"URL":"https:\/\/doi.org\/10.1007\/s10549-013-2777-6","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,22]]}}}